SOURCE: Novacea

October 31, 2006 20:00 ET

Novacea to Hold Conference Call Regarding Oral Vinorelbine Program

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- October 31, 2006 --


Novacea, Inc. (NASDAQ: NOVC) will hold a conference call to provide an update on the company's oral vinorelbine program. This conference call will be preceded by a news release at 8 a.m. Eastern Time (ET) on Wednesday, November 1. The conference call will be webcast live under the investor relations section of Novacea's website at, and will be archived there for 7 days following the call. Please connect to Novacea's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.


5:30 a.m. PT/8:30 a.m. ET, Wednesday, November 1, 2006


Dial-in information:
Domestic: 866.356.3377
International: 1.617.597.5392
Participant code: 22435779

Domestic: 888.286.8010
International: 1.617.801.6888
Passcode: 57441518
About Novacea

Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has three product candidates in clinical trials, including Asentar, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea's second product candidate, oral vinorelbine, is expected to enter a registration trial for metastatic breast cancer in the second half of 2006. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy.

Contact Information

  • Contacts:

    Nina Ferrari

    Paul Laland